Analyst firms · H.C. Wainwright · BLCO

H.C. Wainwright BLCO price target and rating history

Bausch + Lomb Corporation (BLCO) · Health Care

H.C. Wainwright rates Bausch + Lomb Corporation (BLCO) Neutral with a $22 price target, as of its latest action on Nov 2, 2026. It has published 3 rating actions on BLCO since September 2022, including 0 upgrades and 1 downgrade. Across 7 firms with a BLCO price target in the last 12 months, the median target is $21. H.C. Wainwright's $22 is 5% above that.

Current rating
Neutral
Price target
$22
Median target, all firms
$21
Actions on BLCO
3

H.C. Wainwright price target on BLCO

$22$19$152023202420252026
H.C. Wainwright price target on BLCO, each point a stated target, September 2022 to November 2026.

Every H.C. Wainwright rating on BLCO

How other firms rate BLCO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightNeutral$22Nov 2, 2026
BarclaysOverweight$24Oct 7, 2026
Leerink PartnersOutperform$24Sep 9, 2026
UBSBuy$21Jul 28, 2026
Evercore ISIIn-line$18Jan 5, 2026
CitigroupBuy$20Dec 11, 2025
Morgan StanleyOverweight$21Dec 2, 2025

Questions about H.C. Wainwright and BLCO

What is H.C. Wainwright's price target for BLCO?
H.C. Wainwright's latest stated price target for Bausch + Lomb Corporation (BLCO) is $22, from its action on Nov 2, 2026.
What is H.C. Wainwright's rating on BLCO?
H.C. Wainwright rates BLCO Neutral, a neutral rating, as of Nov 2, 2026.
When did H.C. Wainwright last change its view on BLCO?
On Nov 2, 2026, H.C. Wainwright downgrades to Neutral from Buy, price target $22.
How does H.C. Wainwright's BLCO target compare with other analysts?
Across 7 firms with a BLCO price target in the last 12 months, the median target is $21. H.C. Wainwright's $22 is 5% above that.

More BLCO rating histories

All H.C. Wainwright ratingsBLCO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.